Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afatinib as first-line treatment for patient with advanced non-small cell lung cancer harbouring sensitizing EGFR mutations

Next Previous
Trial Profile

Afatinib as first-line treatment for patient with advanced non-small cell lung cancer harbouring sensitizing EGFR mutations

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Sep 2019 Results assessing efficacy, side-effects and resistance mechanisms of first-line afatinib were presented at the 20th World Conference on Lung Cancer
  • 11 Oct 2018 New trial record
  • 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top